Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02273219 · ClinicalTrials.gov registry record · Phase 1
Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02273219 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 30 participants.
The verdict
NCT02273219, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Primary objective is to define the maximum tolerated dose (MTD) for the combination of AEB071 and BYL719. Secondary objectives are to define the safety and tolerability of AEB071 and BYL719.
Interventions
- DRUG BYL719
- DRUG AEB071
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-11-19 |
| Est. Completion | 2018-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02273219
The ClinicalTrials.gov registry entry for NCT02273219 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BYL719 is the first listed.
NCT02273219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02273219 about?
NCT02273219 is a clinical study titled "Trial of AEB071 in Combination With BYL719 in Patients With Melanoma". Primary objective is to define the maximum tolerated dose (MTD) for the combination of AEB071 and BYL719. Secondary objectives are to define the safety and tolerability of AEB071 and BYL719.
What is the current status of trial NCT02273219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-11-19. Estimated completion is 2018-07-02.
What interventions are being tested in trial NCT02273219?
The interventions under investigation include: BYL719 (DRUG), AEB071 (DRUG).
Who is sponsoring clinical trial NCT02273219?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.